The ALS Pharmacy Program for specialized medication management

The ALS Pharmacy Program offers specialized medication management and participation in medical research for people with amyotrophic lateral sclerosis.

Care algorithm to improve the provision of care in cases of ALS.

The ALS care algorithm is meant to strengthen the physician-patient relationship. The algorithm has the potential to improve care for people with ALS.

The ALS app: research and assisting care from home.

The ALS app can be used to track the progression of ALS. People affected can participate in research and assist provision of care from home.

Nusinersen's reality of treatment for SMA.

The effectiveness of Nusinersen is being evaluated in adults with SMA as to the achievement of treatment goals, symptom progression and the patient’s satisfaction with the treatment.

Mobile speech and facial expression analysis in ALS

People with ALS are invited to participate in a research project on digital speech and facial expression analysis via the ALS app.

The SMA Pharmacy Program for specialized medication management

The SMA Pharmacy Program offers specialized drug treatment and participation in medical research for people with spinal muscular atrophy (SMA).

NF-L as a criterion for the provision of care.

We conduct research aimed at establishing the biomarker neurofilament light chain (NF-L) as a criterion for assessing the urgency of care for people with ALS.

APST ALS-Netzwerktreffen: Status of research and care for ALS in Germany, 11.05.2023

On May 11, 2023, the APST ALS Network Meeting will take place in Berlin, followed directly by the MND-Net Meeting. The APST Network Meeting and the MND-Net Meeting serve to discuss current research and care in the field of ALS. The network meeting is attended by ALS experts, researchers and physicians from 14 German ALS outpatient clinics part. There ...

read more

The NfL (neurofilament light chain) progression marker in the ALS app

Why is the biomarker NfL important for people with ALS? The value of the biomarker Neurofilament light chain (NfL) in the blood is suitable for assessing the progression and therapy of ALS. A high blood serum NfL value is often associated with a higher speed in the progression of ALS symptoms. Two recent publications in March this year in the internat ...

read more

Current status of genetics in ALS and Tofersen: ID-ALS study and hardship program.

We would like to briefly update you on the current status (03/01/2023) of the ID-ALS02 study and the transition to the Tofersen Hardship Program After the successful completion of the first part of the ID-ALS study, its continuation was started in October 2022. With the second part of the study (ID-ALS02), so far 1,476 patients with amyotrophic latera ...

read more

People with ALS according to phases of care in the APST network

One body region affected

King’s Stage 1

Two body regions affected

King’s Stage 2

Three body regions affected

King’s Stage 3

Ventilation and/or feeding tube

King’s Stage 4
active participants
Participation initiated

030 81031410

Montag bis Freitag von 9:00 bis 16:00 Uhr

Barbara Hildebrandt

Case- and Network Management

Anja Weiss

Coordination, Specialization on ALS

Dott. Mag. Alessio Riitano

IT operating technology

Felix Kolzarek

Data Management

Dr. Dr. Susanne Spittel

Medical Research

Dr. Senthil Kumar Subramanian

Medical Research

Dip.-Ing. Peggy Schumann

Medical Research

Gönül Akcay

Koordination, Spezialisierung auf Atemhilfen